Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss of $0.78/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss of $0.78/sh

Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

March 5, 2020 4:02 PM EST

- Cash and cash equivalents totaled approximately $306 million at December 31, 2019 -

- Positive AURORA Phase 3 results with voclosporin enabling an NDA submission for the treatment of lupus nephritis (LN) by the end of the second quarter 2020 -

- Continued build out of a top-tier commercial team, highlighted by the appointment of Max Colao, Chief Commercial Officer, focused on launch activities -

- AUDREY Phase2/3 Dry Eye Study remains on-track with results anticipated during the second half of 2020 -

VICTORIA, British Columbia--(BUSINESS... More